Voltammetric sensor based on bimetallic nanocomposite for determination of favipiravir as an antiviral drug

Creative Commons License

Mehmandoust M., Khoshnavaz Y., Tuzen M., ERK N.

MICROCHIMICA ACTA, cilt.188, sa.12, 2021 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 188 Sayı: 12
  • Basım Tarihi: 2021
  • Doi Numarası: 10.1007/s00604-021-05107-2
  • Dergi Adı: MICROCHIMICA ACTA
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, Aerospace Database, Analytical Abstracts, Aqualine, Aquatic Science & Fisheries Abstracts (ASFA), Biotechnology Research Abstracts, Chemical Abstracts Core, Chimica, Communication Abstracts, EMBASE, Food Science & Technology Abstracts, MEDLINE, Metadex, Pollution Abstracts, Civil Engineering Abstracts
  • Anahtar Kelimeler: COVID-19, Favipiravir, Voltammetry, Carbon nanotube, Conductive polymer, Biological sample analysis, THIN-FILMS, ELECTROCHEMICAL SENSOR, COMPOSITE-MATERIALS, GOLD NANOPARTICLES, PASTE ELECTRODE, AU-AG, CARBON, CONDUCTIVITY, POLYMER, PERFORMANCE
  • Ankara Üniversitesi Adresli: Evet

Özet

A novel and sensitive voltammetric nanosensor was developed for the first time for trace level monitoring of favipiravir based on gold/silver core-shell nanoparticles (Au@Ag CSNPs) with conductive polymer poly (3,4-ethylene dioxythiophene) polystyrene sulfonate (PEDOT:PSS) and functionalized multi carbon nanotubes (F-MWCNTs) on a glassy carbon electrode (GCE). The formation of Au@Ag CSNPs/PEDOT:PSS/F-MWCNT composite was confirmed by various analytical techniques, including X-ray diffraction (XRD), ultraviolet-visible spectroscopy (UV-Vis), transmission electron microscopy (TEM), energy-dispersive X-ray spectroscopy (EDX), and field-emission scanning electron microscopy (SEM). Under the optimized conditions and at a typical working potential of + 1.23 V (vs. Ag/AgCl), the Au@Ag CSNPs/PEDOT:PSS/F-MWCNT/GCE revealed linear quantitative ranges from 0.005 to 0.009 and 0.009 to 1.95 mu M with a limit of detection 0.46 nM (S/N = 3) with acceptable relative standard deviations (1.1-4.9 %) for pharmaceutical formulations, urine, and human plasma samples without applying any sample pretreatment (1.12-4.93%). The interference effect of antiviral drugs, biological compounds, and amino acids was negligible, and the sensing system demonstrated outstanding reproducibility, repeatability, stability, and reusability. The findings revealed that this assay strategy has promising applications in diagnosing FAV in clinical samples, which could be attributed to the large surface area on active sites and high conductivity of bimetallic nanocomposite.